The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 501–600 of 1,008
Chan, J. C. N., So, W., Ronald, C. W., Tong, P. C. Y., Wong, R. Y. M., & Yang, X. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0172-6 · Cited by 70
Hellemons, M. E., Persson, F., Bakker, S. J. L., Rossing, P., Parving, H.-H., De Zeeuw, D., & Lambers Heerspink, H. J. (2011) · Diabetes Care · doi:10.2337/dc11-0324 · Cited by 66
Self-citationTelmisartan: just an antihypertensive agent? A literature review
Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632367 · Cited by 65
Yuyun, M. F., Dinneen, S. F., Edwards, O. M., Wood, E., & Wareham, N. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00940.x · Cited by 67
Waeber, B. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.43 · Cited by 66
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics
The DIRECT Programme Study Group (2005) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2005.003 · Cited by 67
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 67
Zhao, J., Tostivint, I. N., Xu, L., Huang, J., Gambotti, L., Boffa, J., Yang, M., Wang, L., Sun, Z., Chen, X., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0607 · Cited by 65
Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
Hellemons, M. E., Mazagova, M., Gansevoort, R. T., Henning, R. H., de Zeeuw, D., Bakker, S. J. L., Lambers-Heerspink, H. J., & Deelman, L. E. (2012) · Diabetes Care · doi:10.2337/dc12-0180 · Cited by 73
Diabetic nephropathy in children and adolescents
Bogdanović, R. (2008) · Pediatric Nephrology · doi:10.1007/s00467-007-0583-2 · Cited by 81
Saklayen, M. G., Gyebi, L. K., Tasosa, J., & Yap, J. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31816d78e9 · Cited by 65
Correa‐Rotter, R., Naicker, S., Katz, I. J., Agarwal, S. K., Valdés, R. H., Kaseje, D. C. O., Rodríguez‐Iturbe, B., Shaheen, F. A. M., & Sitthi‐Amorn, C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09208.x · Cited by 68
The Pleiotropic Effects of Angiotensin Receptor Blockers
Chrysant, S. G., & Chrysant, G. S. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05264.x · Cited by 73
Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease
Patel, D. M., Bose, M., & Cooper, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062218 · Cited by 70
“The negative impact of AngII in DKD has been well documented and it is well accepted that ACE inhibitors (ACEi) and ARBs prevent or delay the progression of DKD in both type 1 and 2 diabetes [10,11,61,62].”
BackgroundAngiotensin-converting enzyme 2 activity in patients with chronic kidney disease
Roberts, M. A., Velkoska, E., Ierino, F. L., & Burrell, L. M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft038 · Cited by 64
“The blockade of the RAS slows, but does not prevent renal and cardiac injury, suggesting that factors beyond the traditional RAS are involved in the progression of disease [5, 6].”
BackgroundAngiotensin Receptor Blockers: Current Status and Future Prospects
Ram, C. V. S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.02.038 · Cited by 68
Microvascular dysfunction and kidney disease: Challenges and opportunities?
Krishnan, S., Suarez‐Martinez, A. D., Bagher, P., Gonzalez, A. L., Liu, R., Murfee, W. L., & Mohandas, R. (2020) · Microcirculation · doi:10.1111/micc.12661 · Cited by 76
Rabi, D. M., Khan, N. A., Vallée, M., Hladunewich, M., Tobe, S. W., & Pilote, L. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70624-x · Cited by 65
Traditional and Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease
Vlagopoulos, P. T., & Sarnak, M. J. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.11.003 · Cited by 72
Diabetic nephropathy in the elderly
Blicklé, J. F., Doucet, J., Krummel, T., & Hannedouche, T. P. (2007) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)80056-5 · Cited by 68
Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria
Riera, M., Anguiano, L., Clotet, S., Roca-Ho, H., Rebull, M., Pascual, J., & Soler, M. J. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00082.2015 · Cited by 63
Race and kidney disease: role of social and environmental factors.
Nzerue, C. M., Demissochew, H., & Tucker, J. K. (2002) · PubMed Central · Cited by 75
Predictors of Chronic Kidney Disease in Long-Term Survivors of Lung and Heart-Lung Transplantation
Canales, M. T., Youssef, P., Spong, R., Ishani, A., Savik, K., Hertz, M., & Ibrahim, H. N. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01458.x · Cited by 63
Initial Implementation of a Web-Based Consultation Process for Patients With Chronic Kidney Disease
Scherpbier-de Haan, N. D., van Gelder, V. A., Van Weel, C., Vervoort, G. M. M., Wetzels, J. F. M., & de Grauw, W. J. C. (2013) · The Annals of Family Medicine · doi:10.1370/afm.1494 · Cited by 62
Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats
Zhang, S., Yang, J., Li, H., Li, Y., Liu, Y., Zhang, D., Zhang, F., Zhou, W., & Chen, X. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.05.017 · Cited by 62
Combination ACEI and ARB therapy: additional benefit in renoprotection?
Taal, M. W., & Brenner, B. M. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200207000-00001 · Cited by 66
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
Parving, H., Andersen, S., Jacobsen, P. K., Christensen, P. K., Rossing, K., Hovind, P. H., Rossing, P. R., & Tarnow, L. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2003.11.003 · Cited by 63
Self-citationKato, S., Maruyama, S., Makino, H., Wada, J., Ogawa, D., Uzu, T., Araki, H., Koya, D., Kanasaki, K., Oiso, Y., et al. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1106-2 · Cited by 61
“IRMA-2 [10] and INNOVATION [11] provided evidence that angiotensin receptor blockers (ARBs) prevent the progression of microalbuminuria to macroalbuminuria in diabetic nephropathy.”
Parving, H. H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Nicolaides, M., Richard, A., et al. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320311434818 · Cited by 60
Self-citationKonoshita, T. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0212-0 · Cited by 64
Thurman, J. M., & Schrier, R. W. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00090-1 · Cited by 62
Yang, Y., Xiao, L., Li, J., Kanwar, Y. S., Liu, F., & Sun, L. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.04.031 · Cited by 68
“Early identification of patients who are prone to develop renal complications would be an important step for their better management during the clinical course of this disease process [5].”
BackgroundSonta, T., Inoguchi, T., Matsumoto, S., Yasukawa, K., Inuo, M., Tsubouchi, H., Sonoda, N., Kobayashi, K., Utsumi, H., & Nawata, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.174 · Cited by 62
Zoja, C., Cattaneo, S. G. D. A., Fiordaliso, F., Lionetti, V., Zambelli, V., Salio, M., Corna, D., Pagani, C., Rottoli, D., Bisighini, C., et al. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00122.2011 · Cited by 60
“Previous studies have shown that drugs which block ANG II synthesis/ biological activity in addition to prevent micro- (44) or macro(38) albuminuria limited CV events in subjects with diabetes (8).”
BackgroundAbdel-Wahab, A. F., Bamagous, G. A., Al-Harizy, R. M., ElSawy, N. A., Shahzad, N., Ibrahim, I. A. A., & Ghamdi, S. S. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.176 · Cited by 68
Karalliedde, J. J., & Viberti, G. C. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001982 · Cited by 70
Rossing, K., Christensen, P. K., Hovind, P. H., & Parving, H. ‐. (2005) · Diabetologia · doi:10.1007/s00125-005-1937-6 · Cited by 61
Self-citationWilliams, B., Poulter, N. R., Mj, B., Davis, M. R., & Sever, P. (2004) · Cited by 61
Cardinal Role of the Intrarenal Renin-Angiotensin System in the Pathogenesis of Diabetic Nephropathy
Kobori, H., Kamiyama, M., Harrison‐Bernard, L. M., & Navar, L. G. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31827c28bb · Cited by 72
Concerted action of the renin–angiotensin system, mitochondria, and antioxidant defenses in aging
de Cavanagh, E. M. V., Piotrkowski, B., & Fraga, C. G. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.02.006 · Cited by 69
Esteghamati, A., Noshad, S., Jarrah, S., Mousavizadeh, M., Khoee, S. H., & Nakhjavani, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft281 · Cited by 60
Onuigbo, M. A. C. (2008) · QJM · doi:10.1093/qjmed/hcn142 · Cited by 59
Pharmacotherapy for hypertension in adults 60 years or older
Musini, V. M., Tejani, A. M., Bassett, K. L., Puil, L. J., & Wright, J. M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000028.pub3 · Cited by 76
Hypertension‐Related Morbidity and Mortality in African Americans—Why We Need to Do Better
Ferdinand, K. C., & Sounders, E. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05295.x · Cited by 65
Shafiq, M. M., Menon, D. V., & Victor, R. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.11.016 · Cited by 69
Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches
Abdel‐Rahman, E. M., Saadulla, L., Reeves, W. B., & Awad, A. S. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1912-5 · Cited by 63
Liu, I.-M., Tzeng, T., Liou, S., & Chang, C. J. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.04.021 · Cited by 59
Siragy, H. M., Awad, A. S., Abadir, P. M., & Webb, R. L. (2003) · Endocrinology · doi:10.1210/en.2003-0010 · Cited by 59
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 65
Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes?
Lai, F. M., Szeto, C., Choi, P. C. L., Ho, K. K. L., Tang, N. L. S., Chow, K. M., Li, P. K., & To, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800219 · Cited by 59
Diabetic patients treated with dialysis: complications and quality of life
Sørensen, V. R., Mathiesen, E. R., Watt, T., Bjorner, J. B., Andersen, M., & Feldt‐Rasmussen, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0810-1 · Cited by 69
Managing cardiovascular and renal risk: the potential of direct renin inhibition
Sever, P., Gradman, A. H., & Azizi, M. (2009) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320309104662 · Cited by 61
Peng, L., Chen, Y., Shi, S., & Wen, H. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02696-w · Cited by 61
“Notably, a combination of ACE inhibitors and ARBs has also been found to be associated with an elevated risk of adverse effects such as acute kidney injury and hyperkalemia [43–45].”
BackgroundInfluentialAbassi, Z. A., Winaver, J. M., & Feuerstein, G. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.018 · Cited by 64
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences
Maneiro, L. L., & Puente-García, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4111908 · Cited by 61
“ In 2001, the IRMA-2 (The Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Trial) study [35] performed in 590 microalbuminuric T2DM patients, showed that treatment with irbesartan (150–300 mg/d) was associated with a dose-dependent reduction in risk of progression”
ResultEvans, M., Bain, S. C., Hogan, S., & Bilous, R. W. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr696 · Cited by 59
“Irbesartan has been shown to reduce endothelial dysfunction, oxidative stress and inflammation [27–33].”
BackgroundMeta-analysis of large outcome trials of angiotensin receptor blockers in hypertension
Cheung, B. M. Y., Cheung, G. T. Y., Lauder, I. J., Lau, C. S. L., & Kumana, C. R. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001931 · Cited by 56
High Prevalence of Microalbuminuria in Chronic Heart Failure Patients
van de Wal, R. M. A., Asselbergs, F. W., Plokker, H. W. T., Smilde, T. D. J., Lok, D. J. A., van Veldhuisen, D. J., van Gilst, W. H., & Voors, A. A. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.05.007 · Cited by 56
Trojanowicz, B., Ulrich, C., Kohler, F. C., Bode, V., Seibert, E., Fiedler, R., & Girndt, M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw206 · Cited by 53
The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review
Ptinopoulou, A., Pikilidou, M. I., & Lasaridis, A. N. (2012) · Hypertension Research · doi:10.1038/hr.2012.157 · Cited by 65
Predictors of Incident Albuminuria in the Framingham Offspring Cohort
O’Seaghdha, C. M., Hwang, S., Upadhyay, A., Meigs, J. B., & Fox, C. S. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.04.013 · Cited by 56
Lü, B., Wen, J., Song, X., Dong, X., Yang, Y., Zhang, Z., Zhao, N. Q., Ye, H. Y., Mou, B., Chen, F. L., et al. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.024 · Cited by 58
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 55
Lakshmanan, A. P., Thandavarayan, R. A., Watanabe, K., Sari, F. R., Harima, M., Giridharan, V. V., Sukumaran, V., Soetikno, V., Arumugam, S., Suzuki, K., et al. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.041 · Cited by 57
The Relationship Between Albuminuria and Hormone Therapy in Postmenopausal Women
Agarwal, M., Selvan, V. A., Freedman, B. I., Liu, Y., & Wagenknecht, L. E. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.02.025 · Cited by 60
Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes
Winkelmayer, W. C., Zhang, Z., Shahinfar, S., Cooper, M. E., Avorn, J., & Brenner, B. M. (2006) · Diabetes Care · doi:10.2337/dc06-0570 · Cited by 59
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 70
“004 for the comparison of systolic blood pressure between the placebo group and the combined irbesartan groups) [143].”
BackgroundACE-I and ARBs in early diabetic nephropathy
Mauer, M., Zinman, B., Gardiner, R., Drummond, K. N., Suissa, S., Donnelly, S. M., Strand, T. D., Kramer, M. S., Klein, R., & Sinaiko, A. R. (2002) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2002.048 · Cited by 57
Safety of Telmisartan in Patients with Arterial Hypertension: An Open-Label Observational Study
Michel, M. C., Bohner, H., K??ster, J., fers, R. F. S., & Heemann, U. W. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00005 · Cited by 68
VersorgungsLeitlinie, N. (2011) · Cited by 58
Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients
Ogawa, H., Kim‐Mitsuyama, S., Matsui, K., Jinnouchi, T., Jinnouchi, H., & Arakawa, K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.010 · Cited by 57
Ferreira, J. P., Zannad, F. M., Butler, J., Filippatos, G. S., Pocock, S., Brueckmann, M., Steubl, D., Schueler, E., Anker, S. D., & Packer, M. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2924 · Cited by 64
Hypertension and kidney disease: A deadly connection
Barri, Y. M. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0098-7 · Cited by 59
Inhibition of the renin–angiotensin system and target organ protection
Iwanami, J., Mogi, M., Iwai, M., & Horiuchi, M. (2009) · Hypertension Research · doi:10.1038/hr.2009.5 · Cited by 60
Diabetes and Stroke Prevention: A Review
Hewitt, J., Guerra, L. C., Fernández‐Moreno, M. D. C., & Sierra, C. (2012) · Stroke Research and Treatment · doi:10.1155/2012/673187 · Cited by 61
“Further, in the presence of diabetic renal disease, micro, or macroalbuminuria, or impaired glomerular filtration, inhibition of the angiotensin-renin system should be recommended as a first line treatment [24].”
BackgroundBoersma, C., Gansevoort, R. T., Pechlivanoglou, P., Visser, S. T., van Toly, F. F. J., den Berg, L. T. W. D. J., de Jong, P. E., & Postma, M. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.013 · Cited by 56
Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
Peleli, M., & Carlström, M. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.12.001 · Cited by 63
Skyler, J. S. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70218-8 · Cited by 71
Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet
Onozato, M. L., Tojo, A., Goto, A., & Fujita, T. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00470.x · Cited by 56
Causland, F. R. M., Lefkowitz, M. P., Claggett, B. L., Packer, M., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Rouleau, J. L., Shi, V. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2421 · Cited by 60
Progression of chronic kidney disease: Can it be prevented or arrested?
Jaber, B. L., & Madias, N. E. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.032 · Cited by 55
Orena, S., Maurer, T. S., She, L., Eudy, R., Bernardo, V., Dash, D., Loria, P., Banker, M. E., Tugnait, M., Okerberg, C. V., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00115 · Cited by 54
“Nonetheless, a significant proportion of patients continue to progress to macroalbuminuria and overt nephropathy (Parving et al., 2001; Ruggenenti et al., 2004).”
BackgroundNovel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium
Levin, A., Reznichenko, A., Witasp, A., Liu, P., Greasley, P. J., Sorrentino, A., Blöndal, T., Zambrano, S. S., Nordström, J., Bruchfeld, A. N., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa121 · Cited by 56
The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design
The DIRECT Programme Study Group, & Chaturvedi, N. (2002) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2002.047 · Cited by 56
Sharma, A. M., & Engeli, S. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.0197-3118.2006.05422.x · Cited by 53
Ko, G. T. C., So, W., Tong, P. C. Y., Coguiec, F. L., Kerr, D., Lyubomirsky, G., Tamesis, B. V., Wolthers, T., Nan, J. H., & Chan, J. C. N. (2010) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-10-26 · Cited by 61
The future of renoprotection: Frustration and promises
Schieppati, A., & Remuzzi, G. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00340.x · Cited by 54
Long-term outcomes of kidney donors
Morgan, B. R., & Ibrahim, H. N. (2011) · Arab Journal of Urology · doi:10.1016/j.aju.2011.06.006 · Cited by 57
Need for better diabetes treatment for improved renal outcome
Rossing, P. R., & de Zeeuw, D. (2011) · Kidney International · doi:10.1038/ki.2010.513 · Cited by 60
Perkins, B. A., Rabbani, N., Weston, A., Ficociello, L. H., Adaikalakoteswari, A., Niewczas, M., Warram, J., Krolewski, A. S., & Thornalley, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035655 · Cited by 54
“Therapeutic agents that induce remission of microalbuminuria in clinical diabetes – such as angiotensin receptor blockers and high dose thiamine [24,25]– decreased levels of damage to glomerular and plasma protein and or levels and flux of related free adducts [18,26].”
BackgroundPersson, F., Lindhardt, M., Rossing, P., & Parving, H.-H. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316652047 · Cited by 54
Self-citationRuilope, L. M., Redón, J., & Schmieder, R. E. (2007) · PubMed Central · Cited by 61
Tan, K. C. B., Chow, W., Ai, V. H. G., & Lam, K. S. L. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.255 · Cited by 54
Regression of glomerular injury by losartan in experimental diabetic nephropathy
Teles, F., Machado, F. G., Fernandes, B. H. V., Malheiros, D. M. A. C., Fujihara, C. K., da Silva, L. F. F., & Zatz, R. (2008) · Kidney International · doi:10.1038/ki.2008.528 · Cited by 58
The Role of Vitamin D in the Pathogenesis and Treatment of Diabetes Mellitus: A Narrative Review
Grammatiki, M., Karras, S., & Kotsa, K. (2019) · Hormones · doi:10.1007/s42000-018-0063-z · Cited by 54
“Microalbuminuria is one of the initial clinical manifestations of DN and a well-known indicator of early renal disease [147].”
Rationale for Double Renin-Angiotensin-Aldosterone System Blockade
Unger, T., & Stoppelhaar, M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.011 · Cited by 56
Diabetic kidney disease: act now or pay later
Atkins, R. C., & Zimmet, P. (2010) · Kidney International · doi:10.1038/ki.2009.509 · Cited by 55
Progression of diabetic nephropathy in type 1 diabetic patients
Najafian, B., & Mauer, M. S. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.08.024 · Cited by 53
Parikh, M. A., Pistenmaa, C. L., Hoffman, E. A., Schwartz, J. E., Madrigano, J., Austin, J. H. M., Kalhan, R., Lovasi, G. S., Watson, K. E., Stukovsky, K. H., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201604-317oc · Cited by 53
Withholding Proven Treatment in Clinical Research
Huston, P., & Peterson, R. L. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451210 · Cited by 55
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.